Mimedx (MDXG) Long-Term Debt Issuances (2020 - 2024)
Mimedx recorded quarterly Long-Term Debt Issuances of -$10.2 million in Q4 2024, down 200.0% quarter-over-quarter from $10.2 million in Q3 2024.
Mimedx's Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at -$10.2 million for Q4 2024.
- In Q4 2024, Long-Term Debt Issuances changed N/A year-over-year to -$10.2 million; the TTM figure through Sep 2025 stood at -$10.2 million (down 134.06% YoY), while the FY2024 annual figure was $19.8 million, changed N/A from the prior year.
- Long-Term Debt Issuances came in at -$10.2 million for Q4 2024 at Mimedx, down from $10.2 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $49.5 million in Q3 2020 to a low of -$10.2 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -10.22 Mn |
| Dec 31, 2024 | -10.22 Mn |
| Sep 30, 2024 | 10.22 Mn |
| Sep 30, 2024 | 10.22 Mn |
| Jun 30, 2024 | -10.22 Mn |
| Jun 30, 2024 | -10.22 Mn |
| Mar 31, 2024 | 30.00 Mn |
| Mar 31, 2024 | 30.00 Mn |
| Sep 30, 2020 | 49.50 Mn |
| Sep 30, 2020 | 49.50 Mn |